Several plausible mechanisms merit consideration: NUCB2 may modulate the production of immunosuppressive cytokines or metabolites that remodel the local tumour microenvironment, thereby fostering conditions conducive to T‐cell dysfunction despite robust transcriptional activation. The gene discussed is NUCB2; the disease is neoplasm.